Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Biotech & pharma
Late-stage development, KEYTRUDA combination potential, orphan drug advantages and multiple tumor expansion position IFx-2.0 for faster adoption and portfolio returns.
Late-stage development, KEYTRUDA combination potential, orphan drug advantages and multiple tumor expansion position IFx-2.0 for faster adoption and portfolio returns.
Oct 13 · 09:04·GlobeNewswire
Healthcare · Biotech & pharma
Milan, Italy, October 13, 2026 – Sibylla Biotech today announced key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial Officer. Both bring significant international corporate expertise, with Dr. Azam contributing more than 25 years of global biopharmaceutical executive, scientific and clinical development leadership. Co-founder and previous CEO Lidia Pieri, PhD, MBA, will remain with the company in the role of Chief Operating Officer. Sibylla also announced the promotion of Elena Ardini, MSc, from Vice President, Research and Development to Chief Scientific Officer. The executive leadership team expansion highlights the company’s progress in validating its differentiated folding interference protein degradation technology and its commitment to bringing its lead program into clinical evaluation.
Oct 13 · 09:00·GlobeNewswire
Healthcare · Biotech & pharma
Oslo, 13 October 2026 – Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, will publish its financial results for the third quarter of 2026 on Thursday, 5 November 2026.
Oct 13 · 06:00·GlobeNewswire
Healthcare · Biotech & pharma
Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, announces that the first clinical data from the ongoing Phase I trial of its lead drug candidate 177Lu-AKIR001 will be presented at the EANM 2026 Congress in Vienna, October 17-21....
Oct 13 · 05:54·PR Newswire
Healthcare · Industrial
Shanghai, China--(October 12, 2026) - Frost & Sullivan officially released the 2026 Global Gene Therapy Industry Development Blue Book in October 2026, in collaboration with industry partners. The report systematically examines the industry's development history, core technology classifications, policy and capital market dynamics, upstream and downstream value chains, bottlenecks in viral vector manufacturing, clinical progress across key indications, reimbursement pathways, and...
Oct 13 · 00:37·Newsfile
Healthcare · Biotech & pharma
Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution SEOUL, South Korea and RALEIGH, N.C., Oct. 12, 2026 -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today...
Oct 13 · 00:15·PR Newswire
Finance · Biotech & pharma
TEL AVIV, Israel, Oct. 12, 2026 -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva’s leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva’s ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy.
Oct 12 · 21:45·GlobeNewswire
Biotech & pharma
LOS ANGELES, Oct. 12, 2026 -- M&A Healthcare Advisors (MAHA), a FINRA-licensed investment bank focused on the healthcare industry, is pleased to announce the sale of Innovo Detox (Innovo), a Pennsylvania-based provider of substance use disorder (SUD) treatment and drug and...
Oct 12 · 20:58·PR Newswire
Biotech & pharma
Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Oct 12 · 20:30·GlobeNewswire
Finance · Healthcare
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on October 10, 2026, under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in September 2026.
Oct 12 · 20:05·GlobeNewswire
SaaS · Healthcare
Mental Health Screening Month: How Tech Is Fixing Therapy’s First-Month Dropout Problem
Mon, 10/12/2026 - 15:35
Body
Every week, millions of people sit down with their mental health therapy provider, take a deep breath, and try to answer a deceptively simple question: “So, how was your week?”
For many, answering that question feels like trying to reconstruct a faded memory. The intense anxiety felt while sitting in traffic on Tuesday or the sudden wave of overwhelm on Thursday evening has lost its sharp edges by Monday morning. Clients often spend the first 15 minutes of a 50-minute appointment trying to recap past events rather than diving into meaningful healing work.
This disconnect between weekly visits is a major contributor to a quiet crisis in mental healthcare: one in four clients discontinue psychotherapy, most after a single session.
At the same time, the market has been flooded with thousands of standalone consumer wellness apps, with research showing that roughly 89% - 92% of mental health applications are abandoned by clients. The reason is simple: self-guided algorithms can’t replace the trust, empathy and safety of a human therapist.
Image
Why Do Standalone Apps Fail Where Clinician-Guided Tools Succeed?
Unlike standalone apps that ask users to navigate their mental health journeys alone, next-generation platforms are designed to operate directly within existing clinical practices. By keeping the mental healthcare provider at the center of the care journey, technology transforms from a passive self-help tool into an active bridge between sessions.
Exemplifying this shift is ReliefAI Health, a digital health venture created through LG NOVA (the North American Innovation Center for LG Electronics), exemplifies this shift. ReliefAI is built as a digital cognitive behavioral therapy (CBT) platform, for providers and clients.
The mobile app enables clients to engage with their care plan daily and capture their mental state throughout their week. This gives providers the ability to understand what is going on with their clients at those crucial times to be better able to assess and support their clients through the therapy process.
Rather than relying on paper notebooks or delayed memory, clients can use voice-journaling features while emotional experiences are still raw, work with interactive CBT exercises, complete clinical assessments and capture real-time mood patterns on their own schedule.
How Does Between-Session Tracking Turn Passive Time Into Active Care?
When technology integrates seamlessly into a clinic’s electronic health records system, the impact on care continuity is profound.
"We see a crucial opportunity for technology to transform mental healthcare by strengthening the vital relationship between therapists and their clients," says the head of LG NOVA Sokwoo Rhee, Executive Vice President of Innovation at LG Electronics. "ReliefAI answers that need."
Instead of starting an appointment with a blank slate, clinicians can review synthesized, objective data beforehand—observing mood trends, completed assessments and key themes from voice entries. Mental health providers begin the session already informed, bypassing routine recaps to focus immediately on deeper therapeutic progress.
Rhee says this continuous model provides several distinct advantages for both clients and providers:
Keeping clients connected to their therapeutic goals throughout the week can significantly reduce early dropout rates and help individuals stay committed through the critical first month.
Tracking real-time insights that allow providers to tailor treatment plans dynamically and show clients tangible evidence of their growth over time.
Remote therapeutic monitoring frameworks give practices structured clinical documentation and continuous engagement capabilities.
What Does a Human-Centered Future for Mental Healthcare Look Like?
As National Depression & Mental Health Screening Month highlights the growing demand for accessible, effective care, the narrative around digital health is evolving. The future of mental healthcare does not belong to standalone algorithms or automated substitutes for human connection, according to Rhee.
Instead, the true breakthrough lies in next-generation platforms giving practitioners the data and visibility they need to do their best work, he says, adding: “By turning the days between sessions into an active, supported part of the healing process, clinician-guided technology can help assure that more people stay in care, build resilience and experience lasting well-being.”
Featured Image
Type of Content
Article
Oct 12 · 18:03·3BL Media
Biotech & pharma
LUCERNE, Switzerland and NEW DELHI, Oct. 12, 2026 -- The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary...
Oct 12 · 18:02·PR Newswire